MDT Medtronic (MDT) Q3 FY25 earnings call
Medtronic delivered its ninth consecutive quarter of mid-single-digit revenue growth, driven by strong performances in Cardiac Ablation Solutions, Neuromodulation, and Diabetes. The company demonstrated significant earnings leverage with improved gross and operating margins, and expects accelerated revenue and EPS growth in Q4 FY25. Strategic investments in key growth drivers like Renal Denervation and Hugo robotics are poised to drive future expansion, despite temporary distributor dynamics impacting U.S. Surgical.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
MDT operating KPIs by quarter
| KPI | Jan 2026 Q3 FY26 | Apr 2026 Q4 FY26 | Jul 2026 Q1 FY27 | Change vs prior quarter |
|---|---|---|---|---|
| Installed base Touch Surgery | 1,000+This quarter, Touch Surgery installations increased over 20% sequentially and have now surpassed 1,000 systems globally.Source: earnings call transcript | 1,400+And our Touch Surgery Digital Ecosystem, well, it continues to represent a clear advantage with over 1,400 installations, up 30% plus sequentially.Source: earnings call transcript | 1,500+Today, Touch Surgery is used in more than 1,500 operating rooms globally, supporting AI-powered insights, collaboration and workflows.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.